Research Article

Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis

Lifang Ye,1,2 Yu Zuo,1 Hanbo Yang,1 Wenli Li,1 Qinglin Peng,1 Xin Lu,1 Guochun Wang,1,2 and Xiaoming Shu1

1Department of Rheumatology, Beijing Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Yinghua East Road, Chaoyang District, Beijing 100029, China
2Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China

Correspondence should be addressed to Xiaoming Shu; sxm992283@hotmail.com

Received 7 August 2018; Revised 22 November 2018; Accepted 29 November 2018; Published 19 February 2019

Aims. The serum concentrations of miRNAs, miR-23a-3p, miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p, were shown to be associated with the immune and inflammatory progressions. We assessed the expressions of these five miRNAs in association with clinical phenotypes and myositis-specific autoantibody-defined subgroups of dermatomyositis (DM).

Methods. The present study included 49 patients with DM and 30 healthy controls. The serum concentrations of miR-23a-3p, miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Associations between the serum concentrations of miRNAs and DM clinical immune phenotypes were examined as well.

Results. The serum concentrations of miR-23b-3p, miR-146a-5p, and miR-150-5p were significantly downregulated in DM patients ($P < 0.001$, $P < 0.001$, and $P = 0.002$, respectively), while miR-146b-5p was remarkably upregulated in DM patients compared with healthy controls ($P = 0.039$). Similarly, the expressions of miR-23b-3p, miR-146a-5p, and miR-150-5p were significantly downregulated in the peripheral blood mononuclear cells (PBMCs) from DM patients. Further study indicated that the serum level of miR-23b-3p was significantly correlated with creatine kinase (CK) ($r = -0.286$, $P = 0.046$) and the serum level of miR-146a-5p was evidently correlated with C-reactive protein (CRP) ($r = -0.358$, $P = 0.012$). Significant correlations were also observed between the serum levels of miR-146b-5p and CRP ($r = -0.347$, $P = 0.014$) and the erythrocyte sedimentation rate (ESR) ($r = -0.287$, $P = 0.046$). In addition, the expression level of miR-146b-5p was upregulated in DM complicated by tumors compared with those without tumors ($P = 0.001$ and $P < 0.001$, respectively). Especially, miR-150-5p was significantly downregulated in DM patients with anti-MDA5 antibodies and anti-NXP2 antibodies compared with those without ($P = 0.017$ and $P = 0.047$, respectively). No significant differences were observed between the four serum microRNAs in patients with and without interstitial lung diseases (all $P > 0.05$).

Conclusion. The results suggest an association between the four immune-related microRNAs and different clinical immune-phenotypes, and this association may regulate the complexity of disease processes through multipathways in DM patients.

1. Introduction

Dermatomyositis is a heterogeneous group of autoimmune inflammatory disorders with a broad range of symptoms, variant organ involvement, disease severities, and outcome, which can be subclassified on the basis of clinical manifestations and myositis-specific autoantibodies (MSAs) [1]. Although researchers thought that its heterogeneity might be characterized by specific genetic factors involved in the different regulated networks, the basis for the distinctive MSA profile and its regulation in DM patients is poorly understood [2].

MicroRNAs (miRNAs) are the key regulators for the expression of related target genes, and the aberrant expression in the immune system may be associated with several human diseases, including inflammation, interstitial lung disease,
and autoimmune diseases [3–6]. In the past ten years, identification of differentially expressed microRNAs (miRNAs) in muscle biopsy samples from patients with inflammatory myopathies caused those miRNAs to be considered new potential molecular pathogenesis or prognostic biomarkers for disease development and progression. Eisenberg et al. firstly reported that several microRNAs were up- and down-regulated in the muscle tissues of polymyositis and dermatomyositis (PM/DM) [7]. In addition, miR-146a and miR-146b were found to be upregulated in the muscle tissues in polymyositis/dermatomyositis (PM/DM). However, miR-146a was downregulated in the study conducted by Yin et al. from China [8]. To date, idiopathic inflammatory myopathy (IIM-) related miRNAs were found by different levels of expressions in the whole blood, peripheral blood mononuclear cells, skeletal muscles, plasma, and serum [9, 10]. Misunova et al. identified serum Let-7b and miR-3907 upregulated and miR-4299 downregulated in DM patients and miR-3907 associated with disease activity [11]. However, these studies did not take into account the diverse myositis-specific autoantibodies which were associated with a distinctive pattern of disease or phenotype [12]. Certain autoantibodies from patients with rheumatic diseases including systemic lupus erythematosus (SLE) have been shown to target key components of microRNA (miRNA) generation [13]. These studies stimulated us to investigate whether different miRNA-mediated regulations exist in DM patients with distinct myositis-specific antibody (MSA) status.

Recently, Prabahar et al. firstly developed an immune-related miRNA database called ImmunemiR. In this database, a total of 245 immune-related miRNAs were recorded within 92 immune-related diseases. Among them, 78% of the immune-related miRNAs were associated with autoimmune diseases which mainly include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and other connective tissue diseases [3]. However, it may be less significant to measure the level of only one of the 245 immune-related miRNAs. According to the ImmunemiR database, miR-23a-3p, miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p were dysregulated in kinds of autoimmune diseases. However, there is limited information on serum miR-23a-3p, miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p associated with clinical phenotypes and MSAs in DM. Therefore, in this condition, we focused on the interactions among multiple miRNAs and examined a possibility that the expression pattern of multiple miRNAs in each patient could be utilized as a more reliable clinical phenotype marker for DM.

In this study, we hypothesized that these five immune-related miRNAs, including miR-23a-3p, miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p, may be associated with different clinical phenotypes and autoantibody statuses. Our hypothesis is that patients with different characteristics and MSA profiles are characterized by specific immune-related miRNA profiles.

2. Material and Methods

2.1. Patients. We selected 49 patients with DM who were hospitalized in China-Japan Friendship Hospital from March 2011 to February 2016 and then collected their serum samples. To further qualify the expressions of microRNAs in DM, we also studied the expression in PBMCs from another 23 patients with DM who were hospitalized in China-Japan Friendship Hospital from November 2016 to August 2018 (clinical data were shown in supplementary material (available here)). All patients fulfilled the criteria of definitive diagnosis of DM according to the Bohan and Peter criteria and 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. All patients were not complicated by infections and other connective tissue diseases. A summary of the clinical and laboratory features of DM patients enrolled in this study is shown in Table 1. This study also included 39 healthy controls, who were gender-matched with the patients. Among them, sera from 30 healthy controls and PBMCs from 9 healthy controls were analyzed. Written informed consent was obtained from all participants, and this study was approved by the Ethics Committee of China-Japan Friendship Hospital (Beijing, China).

2.2. Clinical Assessment. Completing medical histories, physical examinations, and laboratory tests was conducted to all patients during the first visit. Routine laboratory assessments were performed, including the determination of the levels of serum creatine kinase (CK), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), ferritin, high-resolution computerized tomography (HRCT), pulmonary function tests (PFT), and muscle biopsies at the time of visiting at China-Japan Friendship Hospital. ILD was diagnosed based on the findings of HRCT of the chest and pulmonary function tests. ILD classification is based on the clinical-imaging-pathological diagnostic criteria revised by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) in 2013 [14]. All malignancies were confirmed by histopathological findings. The disease activity of patients with DM was evaluated using a visual analogue scale (Physician’s Global Assessment (PGA)) (range: 0–10 cm).

Serum MSAs including anti-Mi-2α, anti-Mi-2β, anti-TIF1-γ, anti-NXP2, anti-SAE1, anti-MDA5, anti-SPR, anti-Jo-1, anti-PL-7, anti-PL-12, anti-OJ, and anti-EJ were detected using commercially available kits (EUROIMMUN, Lübeck, Germany). Anti-HMGCR autoantibodies were detected by the ELISA kit (enzyme-linked immunosorbent assay) (Inova Diagnostics Inc., San Diego, CA, USA).

2.3. Isolation of Serum RNA and PCR. Total RNA was extracted from 1 mL serum using a TRIzol reagent (Invitrogen Corp., Carlsbad, CA, USA) according to the manufacturer’s instructions and eventually was dissolved in 20 μL RNase-free water. The concentration and purity of the small RNAs were measured with an ultraviolet spectrophotometer (Kaiqao, Beijing, China). The ratio of 260/280 was 1.2–2.1. Reverse transcription was performed using the TIANGEN Reverse Transcription kit (TIANGEN Biotech Co. Ltd., Beijing, China) according to the manufacturer’s instructions. The iQTM SYBR Green Supermix (Bio-Rad Laboratories
Inc., Hercules, CA, USA) was used in the quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for relative quantification of miR-23a-3p, miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p in our study with cel-miR-39-3p as an internal control. The primer sequences were specifically designed by RiboBio company (Guangzhou RiboBio Co. Ltd.), which include Bulge-Loop™ hsa-miR-23a-3p RT Primer (ssD809230260), Bulge-Loop™ hsa-miR-23a-3p Forward Primer (ssD809230952), Bulge-Loop™ hsa-miR-23b-3p RT Primer (ssD809230261), Bulge-Loop™ hsa-miR-23b-3p Forward Primer (ssD809230953), Bulge-Loop™ hsa-miR-146a-5p RT Primer (ssD809230159), Bulge-Loop™ hsa-miR-146a-5p Forward Primer (ssD809230851), Bulge-Loop™ hsa-miR-146b-5p RT Primer (ssD809230161), Bulge-Loop™ hsa-miR-146b-5p Forward Primer (ssD809230853), Bulge-Loop™ hsa-miR-150-5p RT Primer (ssD809230169), Bulge-Loop™ hsa-miR-150-5p RT Primer (ssD809230861), and Bulge-Loop™ miR-Reverse Primer (ssD089261711).

The 10 μL of reaction solutions included 1 μL diluted cDNA templates, 0.2 μL reverse primer, 0.2 μL sense primer, 5 μL of SYBR Green Supermix, and a final volume with RNase-free water. qRT-PCR amplification was performed by using the CFX96 RT-PCR System (Bio-Rad Laboratories Inc., Hercules, CA, USA) according to the manufacturer’s instructions. The reactions were incubated in an optical 96-well reaction plate at 95 °C for 5 min, followed by 40 cycles at 95 °C for 20 s, at 60 °C for 20 s, and at 70 °C for 10 s. No signal was detected in negative control (no reverse transcriptase or no template). PCR was simultaneously performed in triplicate for each sample for both the miRNAs and cel-miR-39-3p. To validate the accuracy and specificity of the expected PCR product, we performed the melting curve analysis. Relative miRNA production was determined with the

| Number of patients (n) | All | DM with ILD | DM without ILD | P* value |
|------------------------|-----|-------------|----------------|----------|
| Age at onset (mean ± SD, years) | 47.26 ± 11.44 | 48.16 ± 9.72 | 46.33 ± 13.15 | 0.582 |
| Disease duration, mean of IQR months | 19.04 (3.5–24) | 21.56 (2.5–45) | 17.22 (4.0–22.0) | 0.561 |
| Number of initial treatment, n (%) | 17 (34.6%) | 9 | 8 |  

### Table 1: Clinical features of the DM patients.

| Serological features | All | DM with ILD | DM without ILD | P* value |
|----------------------|-----|-------------|----------------|----------|
| CRP (mg/dL) | 0.64 ± 0.77 | 0.71 ± 0.67 | 0.54 ± 0.82 | 0.133 |
| ESR (mm/h) | 19.22 ± 15.73 | 15.90 ± 3.18 | 12.74 ± 2.60 | 0.006 |
| CK (μ/L) | 609 ± 1190.2 | 596.96 ± 1234.59 | 621.58 ± 242.37 | 0.562 |
| LDH (μ/L) | 315.25 ± 235.00 | 299.2 ± 219.59 | 332.69 ± 254.49 | 0.741 |

**Ferritin (ng/mL)**

| Anti-Jo-1 antibody, n (%) | 5 (10.2%) | 5 | 0 |  
| Anti-MDA5 antibody, n (%) | 11 (22.4%) | 10 | 1 |  
| Anti-TIF1-γ antibody, n (%) | 8 (16.3%) | 0 | 8 |  
| Anti-NXP2 antibody, n (%) | 6 (12.2%) | 1 | 5 |  
| Anti-PL-7 antibody, n (%) | 4 (8.2%) | 4 | 0 |  
| Anti-PL-12 antibody, n (%) | 0 | 0 | 0 |  
| Anti-OJ antibody, n (%) | 0 | 0 | 0 |  
| Anti-EJ antibody, n (%) | 2 (4.8%) | 2 | 0 |  
| Anti-SAE antibody, n (%) | 2 (4.8%) | 1 | 1 |  
| Anti-Mi2 antibody, n (%) | 2 (4.8%) | 0 | 2 |  
| Anti-SRP antibody, n (%) | 1 (2.4%) | 1 | 0 |  
| HMGCGR antibody, n (%) | 1 (2.4%) | 0 | 1 |  
| MSA negative, n (%) | 9 (18.4%) | 2 | 7 |  
| Pulmonary function test, n (%) | 26 (53%) | 19 | 7 |  
| FEV1 | 80.68 ± 19.11 | 75.71 ± 19.03 | 94.71 ± 11.77 | 0.022 |
| FVC | 83.65 ± 21.59 | 79.02 ± 20.68 | 96.22 ± 21.15 | 0.071 |
| DLCO | 61.29 ± 18.29 | 56.27 ± 17.78 | 75.52 ± 11.8 | 0.014 |
| PGA-VAS | 6.12 ± 1.67 | 6.36 ± 1.38 | 5.87 ± 1.94 | 0.321 |

Average values or numbers of each group are shown. Standard deviation (SD), interquartile range (IQR), or percentages are shown. DM: dermatomyositis; ILD: interstitial lung disease; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; CK: creatine kinase; LDH: lactate dehydrogenase; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; DLCO: carbon monoxide diffusing capacity; PGA: physician’s global assessment; VAS: visual analogue scale. **The results of ferritin were partially missed. Data were available for 29 patients. P* value: between DM with ILD and DM without ILD patients.
aid of the $2^{\Delta \Delta Ct}$ method, where Ct was the threshold cycle. Differences in miR-23a-3p, miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p contents in patients with DM compared with the controls were expressed as fold changes.

2.4. Isolation of Human PBMCs and miRNA qRT-PCR. PBMCs were obtained from EDTA-anticoagulated blood by Isopaque-Ficoll gradient centrifugation (Sigma-Aldrich). Cells were cryopreserved at -80°C for quantitative real-time PCR (qRT-PCR) analysis. The total PBMC RNAs were extracted by the miRNasy kit (QIAGEN). To evaluate the miRNA expression levels, qRT-PCR was implemented with Mir-X™ miRNA First-Strand Synthesis Kit and Mir-X™ miRNA qRT-PCR TB Green™ Kit (Takata, Japan). The cycling condition was as follows: 95°C for 30 sec, 95°C for 5 sec (40 cycles), and 60°C for 34 sec. qRT-PCR amplification was performed by using the ABI7500 RT-PCR System (Applied Biosystems, USA) according to the manufacturer’s instructions. The expression of the gene was standardized to the expression amount of U6 and analyzed through the $2^{\Delta \Delta Ct}$ method. The primer sequences (from 5’ to 3’) are listed in Table 2.

2.5. Statistical Analysis. Continuous variables are presented as mean ± standard deviation (SD) or medians and interquartile range (IQR) and frequency and proportions for categorical variables. Categorical data were analyzed using Fisher’s exact test. Comparisons of continuous data were made using the Mann-Whitney U test for two independent samples of data. Multiple comparisons for continuous variables were performed using the analysis of variance (ANOVA). Additionally, correlations with clinical data were assessed using Spearman’s rank correlation coefficient. Statistical analyses were performed using the SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). GraphPad Prism 5 (version 5.01) was used for plotting data. Two-tailed P values less than 0.05 were statistically considered significant.

3. Results

3.1. Clinical Features of the DM Patients. Characteristics of the DM patients are shown in Table 1. Here, 49 DM patients including 25 patients with ILD and 24 patients without ILD were enrolled. The mean age of all patients at the disease onset was 47.26 ± 11.44 years. The median duration of the DM disease was 19.04 months. DM with ILD and DM without ILD subgroups were of similar age, race, and sex. The level of ESR in the DM with ILD group was significantly higher than that in DM without ILD ($P < 0.01$). Although the CK levels in DM with ILD were lower than those in DM without ILD, there was no significant difference between both of them ($P > 0.05$). The serum ferritins were 612.9 ± 624.3 ng/mL in DM with ILD, which were higher than that in patients without ILD. The prevalence of MSAs in the enrolled patients was 81.6%. The rates of the myositis-specific autoantibodies in DM patients are summarized in Table 1. Intriguingly, a patient who was diagnosed with DM without ILD has been found to have anti-MDA5 antibody-positive DM. An anti-TIF1-γ antibody, anti-NX P2 antibody, and HMGCR antibody were mainly found in the DM without ILD groups. There was no statistical difference in the physician’s global assessment and the visual analogue scale (PGA-VAS) between DM with ILD and DM without ILD.

3.2. Different Expression Levels of Immune-Related miRNAs in DM Patients. Five immune-related miRNAs including miR-23a-3p, miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p were analyzed by qPCR in the sera of 49 patients with DM and compared with those of 30 healthy controls (Figure 1(a)). The expression levels of miR-23b-3p, miR-146a-5p, and miR-150-5p were significantly downregulated in the sera of DM (1.99 ± 0.87, 0.26 ± 0.29, and 5.61 ± 4.85, respectively) compared with the HC’s (3.02 ± 1.13, 3.04 ± 3.82, and 19.3 ± 21.2, respectively) ($P < 0.001, P < 0.001$, and $P = 0.002$, respectively). However, the serum levels of miR-146b-5p in patients with DM were significantly upregulated compared with HC’s (17.54 ± 9.44 and 12.99 ± 9.20, respectively, $P = 0.039$). There was no statistical difference between the naive-treatment patients and treated patients in these miRNAs (data not shown).

Additionally, we detected the expression levels of these five microRNAs in PBMCs from another 23 patients and 9 healthy controls (Figure 1(b)). Similarly, the expression levels of miR-23b-3p, miR-146a-5p, and miR-150-5p were significantly downregulated in the PBMCs of DM (2.20 ± 0.52, 1.76 ± 0.48, and 1.27 ± 0.30, respectively) compared with the HC’s (12.00 ± 6.64, 19.26 ± 10.91, and 11.76 ± 5.89, respectively) ($P = 0.038, P = 0.002$, and $P = 0.002$, respectively). But miR-23a-3p and miR-146b-5p were not found to be statistically different between the patients and the healthy controls.

3.3. Correlations between the Levels of MicroRNAs (miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p) and the Clinical Laboratory Parameters of DM. To study whether there were correlations between the dysregulation of the immune-related miRNAs and the different clinical laboratory parameters of DM, correlation analyses between the miRNA levels and CK, lactate dehydrogenase (LDH), ESR, CRP, and ferritins were tested during their first visit. The results showed that the expression levels of serum miR-23b-3p were negatively correlated with CK ($r = -0.286, P = 0.046$, Figure 2(a)), while there were no significant correlations with the ESR, CRP, and LDH. Serum miR-146a-5p levels were rather negatively related to CRP ($r = -0.358, P = 0.012$, Figure 2(b)), while they were not correlated with ESR, CK, and LDH. Significant correlations were found between the miR-146b-5p levels and the CRP ($r = -0.347, P = 0.014$, Figure 2(c)) and ESR ($r = -0.287, P = 0.046$, Figure 2(d)), while there was no significant difference in CK and LDH. Serum levels of miR-150-5p did not reach statistical significance compared to the associated clinical laboratory parameters.

3.4. Associations between Four Immune-Related miRNAs and Myositis-Specific Autoantibodies. To study whether different immune-related miRNAs could contribute to the MSAs in
DM, we explored the four serum levels of immune-related miRNAs in DM patients with different MSA profiles. As shown in Figure 3, serum miR-150-5p levels were significantly downregulated in DM patients with anti-NXP2 antibodies (3.58 ± 2.02, 11 cases) compared with those without anti-NXP2 antibodies (6.19 ± 5.27, 38 cases; P = 0.047) (Figure 3(a)). In addition, serum miR-150-5p levels were also significantly downregulated in DM patients with anti-MDA5 antibodies (3.58 ± 2.02, 11 cases) compared with those without anti-MDA5 antibodies (6.19 ± 5.27, 38 cases; P = 0.017) (Figure 3(b)). However, no significant differences were observed between the serum levels of miR-23b-3p, miR-146a-5p, and miR-146b-5p in DM patients with MSAs (anti-ARS, anti-SAE, anti-TIF1-γ, anti-Mi-2, anti-SRP, and HMGCR autoantibodies) and those patients without MSAs (data not shown). However, we did not find significant correlations between these five immune-related miRNA expressions of PBMCs and MSAs in DM patients (data not shown).

### Table 2

| miRNA/snRNA | Primer sequences |
|-------------|------------------|
| miR-23a-3p  | Forward: CGATACATTGCAGGGATTCC |
| miR-23b-3p  | Forward: CGATACATTGCAGGGATTAC |
| miR-146a-5p | Forward: CGGTGAACCTGAATTCCATGGGT |
| miR-146b-5p | Forward: CGGTGAACCTGAATTCCATGGGT |
| miR-150-5p  | Forward: TGGAAGCTTCAGAATTAC |
| U6          | Forward: TGGAAGCTTCAGAATTAC |

**Figure 1:** Comparison of the levels of microRNAs (miR-23a-3p, miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p) in sera of DM patients and the healthy controls (49 DM and 30 control cases) and in PBMCs between 23 DM patients and 9 healthy controls by quantitative reverse transcription-PCR (qRT-PCR). Values shown were normalized to cel-miR-39-3p. Differences between the levels were expressed as relative expression using the 2^{-ΔΔCt} method. Data were expressed as mean ± standard deviation (SD). 2-group comparisons were analyzed using the Mann-Whitney U test. All P values were two-sided, and P < 0.05 was statistically considered significant. ***P < 0.001, **P < 0.01, and *P < 0.05. **

3.5. **Correlations between the Levels of MicroRNAs (miR-23b-3p, miR-146a-5p, miR-146b-5p, and miR-150-5p) and Organ Involvement in DM Patients.** We further examined whether organ involvement would be associated with specific miRNAs in DM patients. As shown in Figure 4(a), no significant differences were observed between the serum levels of miR-23b-3p, miR-146a-5p, and miR-150-5p in DM patients with and without ILD. Significant difference was observed only between serum levels of miR-146b-5p in DM patients with and without ILD (P = 0.013); however, it did not reach statistical significance between DM patients with ILD and...
HCs ($P > 0.05$). To verify whether the types of ILD could be associated with specific miRNAs in DM, we further categorized ILD into organized pneumonia (OP, $n = 15$), nonspecific interstitial pneumonia (NSIP, $n = 8$), and usual interstitial pneumonia (UIP, $n = 2$). The serum levels of miR-150-5p were significantly higher in DM with NSIP or OP than those with UIP ($P = 0.044$ and $P = 0.029$, respectively, Figure 4(b)). In addition, no significant differences were observed between the serum levels of miR-23b-3p, miR-146a-5p, and miR-146b-5p in DM patients with NSIP, OP, or UIP.

It has been extensively reported that cancer was a severe complication which increased mortality in DM patients. However, no attempt has been made to evaluate the associations between immune-related miRNAs and cancer in DM patients. Hence, we simultaneously explored the correlations between the candidates of four immune-related miRNAs and cancer in DM patients. As shown in Figure 4(c), the expression levels of serum miR-146b-5p were higher in DM patients with cancer than those without cancer and HCs ($P = 0.001$ and $P < 0.001$, respectively). We did not observe associations between the expression levels of serum miR-23a-3p, miR-146a-5p, and miR-150-5p in DM patients with cancer and those without.

4. Discussion

Our study shows that the four immune-related miRNAs are differentially expressed in DM patients. The major findings in this study indicated that (1) decreased expression level of serum miR-23b was negatively correlated with CK, (2) decreased expression level of serum miR-150-5p was specifically correlated with anti-MDA5 and anti-NXP2 autoantibodies in DM patients, and (3) expression level of serum miR-146b-5p was significantly higher in DM patients with cancer than those without, while these four immune-related miRNAs were not significantly associated with ILD in DM patients. These results indicated that immune-related miRNAs could reflect the different phenotypes in DM patients.

DM is recognized to be a heterogeneous disease, which is associated with MSAs and possibly consists of distinct disease entities such as antisynthetase syndrome (ASS),
anti-MDA5-positive DM, and cancer-associated DM. In agreement with this, our results show that the serum levels of immune-related miRNAs clearly differed between the clinical phenotypes and autoantibody groups. In particular, patients with anti-MDA5 and anti-NXP2 autoantibodies presented downregulated miR-150-5p. So far, however, no data are yet available on the biological effects of microRNAs regarding the autoantibodies in DM. Our study firstly described that MSAs correlated with the immune-related miRNAs in DM. Wuttge et al. reported that circulating miRNAs were different between systemic sclerosis with ACA- and anti-DNA topoisomerase I antibody-positive patients and those without [15]. Our results were indirectly proven by the recent reported observations that the expression of miR-150-5p in the peripheral mononuclear leukocytes (PB MCs) from primary Sjögren’s syndrome (pSS) was significantly downregulated compared to the healthy controls, which was potentially linked to B cell functions [16]. Inversely, Chauhan et al. reported that different sets of miRNAs were dysregulated in SLE patients with different autoantibody profiles. One of the miRNAs was miR-150 upregulated in anti-dsDNA+ENA+SLE patients compared with the healthy controls [17]. However, the mechanism by which miRNA participates in the formation of autoantibodies is still not clear. Xia et al. studied that microRNA-326 could upregulate B lymphocyte activity and autoantibody production through regulating Ets-1 in lupus disease [18]. Decreased miR-1246 expression through the AKT-P53 signaling pathway and the downstream effect on the expression of EBF1 leads to further activation of B cells in SLE [19]. Although the exact regulatory mechanism of miRNAs on the autoantibody production was not understood, these data truly suggest that autoimmune rheumatic diseases may be linked at molecular epigenetic levels through their circulating miRNA profiles to autoantibody profiles. Previous studies showed that miR-150 was selectively expressed in mature, resting B and T cells and also affected B cell differentiation and development, which indicated that dysregulation of miR-150 strikingly affected antibody production [20–22]. These studies provide us solid theories to further study the exact pathogenesis of regulatory B cells and autoantibody production in DM. We speculate that decreased expression of miR-150-5p controls B cell development and autoantibody production through regulating target genes (Figure 5). Further study may be required to explore the exact mechanism of downregulated serum miR-150-5p control MSA especially anti-MDA5 and anti-NXP2 autoantibody production in DM.

There were several studies which investigated the correlations between serum microRNAs and clinical phenotypes in DM patients (Table 3) [8, 11, 23–25]. Inoue and colleagues suggested that the serum and the skin expression of miR-233 were both downregulated in DM patients with Gottron’s papules and clinically amyopathic DM patients [24]. Several serum microRNAs, such as miR-7 and miR-21-5p, were observed with dysregulation in DM patients. Upregulation of serum miR-21-5p was correlated with serum immunoglobulin G levels, while a decrease in serum expression of miR-7 was associated with skin involvement in DM patients [25, 26]. These studies, therefore, may show that the serum levels of microRNAs are useful markers for the diagnosis or evaluation of different clinical phenotypes in DM patients.
We firstly found that serum miR-23b-3p levels were correlated significantly with CK, but its role in the skeletal muscle damage in DM is still unknown. There is an interesting study that shows urine miR-23b-3p was significantly downregulated in nonambulant Duchenne muscular dystrophy (DMD) patients compared with age-matched healthy controls [27]. This study suggested that the downregulation of miR-23b-3p was a marker of skeletal damage, which is similar to our study. In addition, several studies have also revealed that miR-23b-3p may exert an effect on different types of immune cells, including monocytes, macrophages, and dendritic cells (DCs) [28, 29]. Moreover, it has been reported that miR-23b-3p prevents multiple autoimmune diseases through the regulation of inflammatory cytokine pathways, such as NF-κB, tumor necrosis factor- (TNF-) α, interleukin- (IL-) 1β, and IL-17 [30]. Innate immune cells

![Graph a](image1.png)  
![Graph b](image2.png)  
![Graph c](image3.png)

**Figure 4:** Correlations between serum miRNA levels and organ involvement in DM patients. (a) Significant difference was observed between expression levels of serum miR-146b-5p in DM patients with and without ILD ($P = 0.013$). (b) The serum levels of miR-150-5p were significantly higher in DM patients with NSIP than in those with UIP ($P = 0.044$ and $P = 0.029$, respectively). (c) The expression levels of serum miR-146b-5p were higher in DM patients with cancer than in those without cancer and HCs ($P = 0.001$ and $P < 0.001$, respectively). Multiple comparisons for continuous variables were performed using the analysis of variance (ANOVA). ***$P < 0.001$, **$P < 0.01$, and *$P < 0.05$. 

![Graph a](image1.png)  
![Graph b](image2.png)  
![Graph c](image3.png)
such as DCs and macrophages and inflammatory mediators such as IL-17 and TNF-α have been shown to be involved in the pathogenesis of skeletal muscle damage, which leads to high serum CK levels [2]. The studies lead us to speculate that the downregulation of miR-23b-3p may participate in muscle damage through targeting immune cells and inflammatory mediators (Figure 5).

The downregulation of serum miR-146a-5p has negatively correlated with CRP, while there was no association with MSAs, CK, and organ involvement in DM patients. This

Figure 5: Schematic diagram of the regulation role of four immune-related miRNAs in DM. IRAK1: interleukin-1 receptor-associated kinase 1; TRAF6: tumor necrosis factor receptor-associated factors 6; IKKa: inhibitor kappa B kinase α; IKKβ: inhibitor kappa B kinase β; IKKγ: inhibitor kappa B kinase γ; IkBα: inhibitor k binding α; IRF5: interferon regulatory factor 6; NF-κB: nuclear factor-k-gene binding; TAK1: transforming growth factor-activated kinase-1; TAB1: transforming growth factor-beta-activated protein kinase 1-binding protein 1; TAB2: transforming growth factor-beta-activated protein kinase 1-binding protein 2; TAK1: transforming growth factor-β-activated kinase 1.

Table 3: Serum/plasma expression of miRNAs correlated with clinical phenotypes in DM.

| miRNAs     | Regulation | Clinical phenotypes                                      | Ref     |
|------------|------------|---------------------------------------------------------|---------|
| miR-4442   | Up         | Skeletal disease activities                              | [23]    |
| miR-146a   | Down       | Inflammation                                            | [8]     |
| Let-7b     | Up         | Disease activity                                        | [11]    |
| miR-3907   | Up         | Gottron’s eruption                                      | [26]    |
| miR-4299   | Down       | Gottron’s papules                                       | [24]    |
| miR-23b-3p | Down       | CK                                                      |         |
| miR-146a-5p| Down       | CRP                                                     |         |
| miR-146b-5p| Up         | ESR, CRP, and DM complicated with cancer                | Our study|
| miR-150-5p | Down       | Anti-MDA5 and anti-NXP2 antibody                         |         |

DM: dermatomyositis; CK: creatine kinase; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; anti-MDA5: anti-melanoma differentiation-associated gene 5; anti-NXP2: anti-nuclear matrix protein-2
may be explained by the knowledge of miR-146a-5p involved in the inflammation progression and autoimmune diseases [31]. In line with our study, Okada et al. also found that serum miR-146a-5p levels tended to be downregulated in patients with dermatomyositis with CC genotype, which associated with disease activity [32]. Recent findings further showed that miR-146a-5p downregulated in the macrophage of DM patients contributes to the infiltration of inflammatory macrophages in DM by targeting TRAF6 and affecting the IL-17/ICAM-1 pathway [8]. The overexpression of miR-146a is induced by LPS-mediated inflammatory responses and leads to the downregulation of target genes interleukin-1 receptor-associated kinase (IRAK) 1 and tumor necrosis factor receptor-associated factor 6 (TRAF6), thus serving as a negative feedback for immune activation [33]. These studies may prompt us to speculate that downregulated serum miR-146a-5p overexpresses its target genes IRAK1 and TRAF6, then activates the NF-κB signaling pathway and induces the production of type I interferons, OAS1, and Mx1, and consequently contributes to the pathogenesis of DM (Figure 5).

miR-146b-5p is a family of miR-146, sharing a seed sequence. Therefore, we further studied the serum expression of miR-146b-5p in DM patients. Our results showed that the high expression of serum miR-146-5p was negatively correlated with ESR and CRP, respectively. These results are in agreement with Eisenberg et al.’s study who found that miR-146b-5p was overexpressed in DM patients [3]. miR-146b-5p level was upregulated in rheumatoid arthritis patients compared to healthy controls. The upregulation of miR-146b-5p was shown to be related to the infiltration of IL-17-producing T cells in the RA synovium and to a higher expression of IL-17 within T cells which expanded from the peripheral blood mononuclear cells (PBMCs) [34]. In addition, we also found that serum expression of miR-146b-5p in DM patients with cancer was higher than that in patients without. Previous studies reported that expression of miR-146b-5p significantly increased in solid cancers. The upregulation of miR-146b-5p could downregulate the expression levels of its target genes to mediate the proliferation, invasion, and migration of cancer cells [35–37]. These studies indicated that miR-146b-5p may be to some extent a biomarker for cancer associated with DM. Due to the small sample size of cancer associated with DM in the study, the result should be confirmed by prospective studies in a large sample size of cancer associated with DM.

In our study, we also found that patients with anti-Jo-1, anti-PL-7, anti-EJ, and anti-MDA5 antibodies are more likely to have interstitial lung disease, while the DM patients with an anti-TIF1-γ antibody mainly were without ILD (Table 1), which is consistent with previous studies [12, 38]. Unexpectedly, our study did not find that the four serum immune-related miRNAs (miR-23b-3p, miR146a-5p, miR-146b-5p, and miR-150-5p) were not specifically associated with ILD in DM. However, there were interesting findings that (1) serum levels of miR-146b-5p in DM patients with ILD were lower than those in patients without ILD (P = 0.013) but did not reach statistical significance between DM patients with ILD and HCs (P > 0.05) and (2) serum expression of miR-150-5p in DM with UIP was much lower than that in DM with NSIP and OP. Therefore, further study should be conducted to explore the exact roles of miR-146b-5p and miR-150-5p in DM with different types of ILD. In accordance with our study, Honda et al. also suggested that serum miR-150 was downregulated in systemic sclerosis (SSc) but not significantly correlated with SSc with ILD [39].

There are some limitations of this explorative study: firstly, the study has cross-sectional design. Data should therefore be interpreted with some caution until future verification in large validation cohorts. Secondly, the comparatively small numbers of patients with MSAs were analyzed for miRNA expression which may lead to bias results. Another drawback is that a functional study for each miRNA was not performed. Further study is undergoing to explore the function of these serum miRNAs and their pathological role in DM.

However, to our knowledge, this is the first time to link the expression levels of specific serum miRNAs to MSA profiles in DM. Serum immune-related miRNAs may be involved in the pathogenesis and manifestations of the various DM subtypes.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

This study was funded by the Youth Program of the National Natural Sciences Foundation of China (Grant No. 81601367, 81401363, and 81601833), the Major Research Plan of the National Natural Science of China (Grant No. 91542121), and the Capital Health Research and Development of Special Projects (Grant No. 2014-4-4062).

Supplementary Materials

Supplementary Table 1 shows the clinical features of the DM patients associated with PBMCs. (Supplementary Materials)

References

[1] P. W. Wolstencroft and D. F. Fiorentino, "Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies," Current Rheumatology Reports, vol. 20, no. 5, p. 28, 2018.
[2] F. W. Miller, J. A. Lamb, J. Schmidt, and K. Nagaraju, "Risk factors and disease mechanisms in myositis," Nature Reviews Rheumatology, vol. 14, no. 5, pp. 255–268, 2018.
[3] A. Prabahar and J. Natarajan, "ImmuneRiM-a database of prioritized immune miRNA disease associations and its interactome," MicroRNA, vol. 6, no. 1, pp. 71–78, 2017.
A. Srivastava, P. Nikamo, W. Lohcharoentuk et al., “MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis,” Journal of Allergy and Clinical Immunology, vol. 139, no. 2, pp. 550–561, 2017.

W. E. Lawson, T. S. Blackwell, and J. Gauldie, “Let it be: micro-RNAs impact interstitial lung disease,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 1, pp. 1–2, 2011.

P. N. Garo and G. Murugaiyan, “Contribution of microRNAs to autoimmune diseases,” Cellular and Molecular Life Sciences, vol. 73, no. 10, pp. 2041–2051, 2016.

I. Eisenberg, A. Eran, I. Nishino et al., “Distinctive patterns of microRNA expression in primary muscular disorders,” Proceedings of the National Academy of Sciences, vol. 104, no. 43, pp. 17016–17021, 2007.

Y. Yin, F. Li, J. Shi, S. Li, J. Cai, and Y. Jiang, “miR-146a regulates inflammatory infiltration by macrophages in polymyositis/dermatomyositis by targeting TRAF6 and affecting IL-17/ICAM-1 pathway,” Cellular Physiology and Biochemistry, vol. 40, no. 3–4, pp. 486–498, 2016.

J. E. Parkes, P. J. Day, H. Chinoy, and J. A. Lamb, “The role of microRNAs in the idiopathic inflammatory myopathies,” Current Opinion in Rheumatology, vol. 27, no. 6, pp. 608–615, 2015.

S. Gao, H. Luo, H. Zhang, X. Zuo, L. Wang, and H. Zhu, “Using multi-omics methods to understand dermatomyositis/polymyositis,” Autoimmunity Reviews, vol. 16, no. 10, pp. 1044–1048, 2017.

M. Misunova, G. Salinas-Riester, S. Luthin et al., “Microarray analysis of circulating micro RNAs in the serum of patients with polymyositis and dermatomyositis reveals a distinct disease expression profile and is associated with disease activity,” Clinical and Experimental Rheumatology, vol. 34, no. 1, pp. 17–24, 2016.

N. J. McHugh and S. L. Tansley, “Autoantibodies in myositis,” Nature Reviews Rheumatology, vol. 14, no. 5, pp. 290–302, 2018.

A. Jakymiw, K. Ikeda, M. J. Fritzler, W. H. Reeves, M. Satoh, and E. K. L. Chan, “Autoimmune targeting of key components of RNA interference,” Arthritis Research & Therapy, vol. 8, no. 4, article R87, 2006.

W. D. Travis, U. Costabel, D. M. Hansell et al., “An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias,” American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 6, pp. 733–748, 2013.

D. M. Wuttge, A. L. Carlsen, G. Teku et al., “Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA in systemic sclerosis,” Rheumatology, vol. 54, no. 11, pp. 2100–2107, 2015.

J. Q. Chen, G. Papp, S. Poliska et al., “MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren’s syndrome,” PLoS ONE, vol. 12, no. 3, article e0174585, 2017.

S. K. Chauhan, V. V. Singh, R. Rai, M. Rai, and G. Rai, “Differential microRNA profile and post-transcriptional regulation exist in systemic lupus erythematosus patients with distinct autoantibody specificities,” Journal of Clinical Immunology, vol. 34, no. 4, pp. 491–503, 2014.

Y. Xia, J. H. Tao, X. Fang et al., “MicroRNA-326 upregulates b cell activity and autoantibody production in lupus disease of MRL/lpr mice,” Molecular Therapy - Nucleic Acids, vol. 11, pp. 284–291, 2018.

S. Luo, Y. Liu, G. Liang et al., “The role of microRNA-1246 in the regulation of B cell activation and the pathogenesis of systemic lupus erythematosus,” Clinical Epigenetics, vol. 7, no. 1, pp. 1–24, 2015.

C. Xiao, D. P. Calado, G. Galler et al., “miR-150 controls B cell differentiation by targeting the transcription factor c-Myl,” Cell, vol. 131, no. 1, pp. 146–159, 2007.

S. Monticelli, K. M. Ansel, C. Xiao et al., “MicroRNA profiling of the murine hematopoietic system,” Genome Biology, vol. 6, no. 8, article R71, 2005.

B. Zhou, S. Wang, C. Mayr, D. P. Bartel, and H. F. Lodish, “miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely,” Proceedings of the National Academy of Sciences, vol. 104, no. 17, pp. 7080–7085, 2007.

T. Hirai, K. Ikeda, H. Tsushima et al., “Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis,” Inflammation and Regeneration, vol. 38, no. 1, pp. 1–9, 2018.

K. Inoue, M. Jinnin, K. Yamane et al., “Down-regulation of miR-232 contributes to the formation of Gottron’s papules in dermatomyositis via the induction of PKCe,” European Journal of Dermatology, vol. 23, no. 2, pp. 160–167, 2013.

S. Shimada, M. Jinnin, A. Ogata et al., “Serum miR-21 levels in patients with dermatomyositis,” Clinical and Experimental Rheumatology, vol. 31, no. 1, pp. 161–162, 2013.

Y. Oshikawa, M. Jinnin, T. Makino et al., “Decreased miR-7 in the skin and sera of patients with dermatomyositis,” Acta Dermato-Venereologica, vol. 93, no. 3, pp. 273–276, 2013.

F. Catapano, J. Domingos, M. Perry et al., “Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients,” Epigenomics, vol. 10, no. 7, pp. 875–889, 2018.

B. Cui, W. Liu, X. Wang et al., “Brucella Omp25 upregulates miR-155, miR-21-5p, and miR-23b to inhibit interleukin-12 production via modulation of programmed death-1 signaling in human monocyte/macrophages,” Frontiers in Immunology, vol. 8, p. 708, 2017.

J. Wu, C. Ji, F. Cao, H. Lui, B. Xia, and L. Wang, “Bone marrow mesenchymal stem cells inhibit dendritic cells differentiation and maturation by microRNA-23b,” Bioscience Reports, vol. 37, no. 2, article BSR20160436, 2017.

R. Hu and R. M. O’Connell, “MiR-23b is a safeguard against autoimmunity,” Nature Medicine, vol. 18, no. 7, pp. 1009–1010, 2012.

M. R. Paterson and A. J. Kriegel, “MiR-146a/b: a family with shared seeds and different roots,” Physiological Genomics, vol. 49, no. 4, pp. 243–252, 2017.

Y. Okada, M. Jinnin, T. Makino et al., “MIRSNP rs 2910164 of miR-146a is associated with the muscle involvement in polymyositis/dermatomyositis,” International Journal of Dermatology, vol. 53, no. 3, pp. 300–304, 2014.

K. D. Taganov, M. P. Boldin, K. J. Chang, and D. Baltimore, “NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune
responses,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 33, pp. 12481–12486, 2006.

[34] A. V. Churov, E. K. Oleinik, and M. Knip, “MicroRNAs in rheumatoid arthritis: altered expression and diagnostic potential,” *Autoimmunity Reviews*, vol. 14, no. 11, pp. 1029–1037, 2015.

[35] Y. Li, H. Zhang, Y. Dong et al., “MiR-146b-5p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer,” *Journal of Cancer*, vol. 8, no. 9, pp. 1704–1716, 2017.

[36] Y. Zhu, G. Wu, W. Yan, H. Zhan, and P. Sun, “miR-146b-5p regulates cell growth, invasion, and metabolism by targeting PDHB in colorectal cancer,” *American Journal of Cancer Research*, vol. 7, no. 5, pp. 1136–1150, 2017.

[37] C. R. Lima, M. V. Geraldo, C. S. Fuziwara, E. T. Kimura, and M. F. Santos, “MiRNA-146b-5p upregulates migration and invasion of different papillary thyroid carcinoma cells,” *BMC Cancer*, vol. 16, no. 1, p. 108, 2016.

[38] M. Mejía, D. Herrera-Bingas, D. I. Pérez-Román et al., “Interstitial lung disease and myositis-specific and associated autoantibodies: clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF),” *Respiratory Medicine*, vol. 123, pp. 79–86, 2017.

[39] N. Honda, M. Jinnin, T. Kira-Etoh et al., “miR-150 downregulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin β3,” *American Journal of Pathology*, vol. 182, no. 1, pp. 206–216, 2013.